Published in J Clin Oncol on January 15, 2003
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A (2012) 1.99
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. Blood (2012) 1.73
Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci U S A (2005) 1.62
Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem (2008) 1.33
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A (2011) 1.15
ADME of antibody-maytansinoid conjugates. AAPS J (2012) 1.03
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs (2016) 0.90
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res (2009) 0.89
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul) (2015) 0.86
Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res (2014) 0.84
Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett (2011) 0.83
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials. J Ocul Pharmacol Ther (2015) 0.79
Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J (2014) 0.79
Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol (2014) 0.79
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs (2014) 0.78
Antibody Drug Conjugates: Nonclinical Safety Considerations. AAPS J (2015) 0.77
World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs (2014) 0.77
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn (2016) 0.75
Protein based therapeutic delivery agents: Contemporary developments and challenges. Biomaterials (2017) 0.75
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol (2016) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol (2002) 3.53
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev (2004) 2.77
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol (2006) 2.48
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol (2009) 2.11
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 1.87
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol (2012) 1.84
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2006) 1.84
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol (2003) 1.80
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol (2007) 1.78
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Raf: a strategic target for therapeutic development against cancer. J Clin Oncol (2005) 1.63
A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clin Cancer Res (2013) 1.58
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci (2005) 1.55
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res (2011) 1.53
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer (2007) 1.51
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Is there an antiandrogen withdrawal syndrome with enzalutamide? BJU Int (2014) 1.47
Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology (2009) 1.47
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer (2008) 1.39
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica (2012) 1.39
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs (2012) 1.38
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res (2008) 1.34
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther (2003) 1.33
Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.31
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med (2002) 1.28
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res (2010) 1.28
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst (2013) 1.27
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys (2004) 1.25
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol (2013) 1.24
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.23
Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol (2004) 1.22
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res (2008) 1.21
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant (2010) 1.21
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer (2010) 1.21
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Eur J Cancer (2008) 1.20
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol (2013) 1.19
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol (2012) 1.17
Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem (2014) 1.16
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res (2008) 1.14
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res (2011) 1.14
Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer (2003) 1.12
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res (2010) 1.12
Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer (2006) 1.12
Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol (2006) 1.11
Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate (2008) 1.11
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol (2008) 1.11